Skip to main content
Fuji Pharma Co.,Ltd. logo

Fuji Pharma Co.,Ltd. — Investor Relations & Filings

Ticker · 4554 ISIN · JP3816200004 LEI · 529900L1XVCEHVKHAM60 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2022-12-21 Regulatory Filings
Country JP Japan
Listing T 4554

About Fuji Pharma Co.,Ltd.

https://www.fujipharma.jp/english/ir/

Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription medical products. The company's primary focus is on women's healthcare, including hormonal preparations for obstetrics and gynecology, alongside curative medicines and in-vitro diagnostics. Its portfolio includes both specialty and generic drugs. In addition to developing its own pharmaceuticals, Fuji Pharma offers extensive contract manufacturing services for a wide variety of dosage forms, such as solids, injections, ointments, creams, and liquids, for domestic and international clients.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings
2022-12-21 Japanese
有価証券報告書－第58期(令和3年10月1日－令和4年9月30日)
Annual Report
2022-12-21 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the 3rd Quarter Report (第３四半期報告書). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the financial statements, which is a standard regulatory requirement in Japan. Since it is a specific regulatory filing that does not fit into the 'Interim/Quarterly Report' (IR) category (which would be the report itself) or other specific categories, it falls under the 'Regulatory Filings' (RNS) category.
2022-08-08 Japanese
四半期報告書－第58期第3四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Fuji Pharma Co., Ltd., covering the third quarter of the 58th fiscal period (April 1, 2022, to June 30, 2022). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, along with notes on accounting policies. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2022
2022-08-08 Japanese
四半期報告書－第58期第2四半期(令和4年1月1日－令和4年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Fuji Pharma Co., Ltd., covering the second quarter of the 58th fiscal year (period ending March 31, 2022). It contains comprehensive financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management analysis and notes. This fits the definition of an Interim/Quarterly Report (IR). H1 2022
2022-05-09 Japanese
四半期報告書－第58期第1四半期(令和3年10月1日－令和3年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Fuji Pharma Co., Ltd., covering the first quarter of the 58th fiscal period (October 1, 2021, to December 31, 2021). It contains detailed financial statements, including the consolidated balance sheet, income statement, and comprehensive income statement, along with notes on accounting policies. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2022
2022-02-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.